Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT01117246 Completed - Clinical trials for Secondary Malignant Neoplasm of Bone

Pilot Study for Palliation of Pain in Bone Metastases by MR-HIFU

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to confirm the safety and technical of MRI guided High Intensity Focused Ultrasound (HIFU) for Palliation for Pain of Skeletal Metastases. MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate tissue. The MRI system identifies the ultrasound path and monitors heat rise in the tissue. The goal of the study is to show treatment safety and effectiveness. MR-guided HIFU will be performed in patients who pass inclusion/exclusion criteria.

NCT ID: NCT01115790 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Phase 1 Study in Participants With Advanced Cancer

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1[chk 1]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three different groups of participants; those with squamous cell cancer of the head and neck that has recurred or spread to other parts of the body, those with squamous non-small cell lung cancer that has recurred or spread, and those with squamous cell cancer of the anus that is not curable by existing therapy.

NCT ID: NCT01114958 Completed - Neoplasm Metastasis Clinical Trials

Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases

Start date: September 3, 2009
Phase: Phase 1
Study type: Interventional

This phase I study proposes the use of systemic thiosulfate rescue to allow supradose intra-arterial cisplatin delivery to lung tumors. Eligible patients would be those with at least one lung lesion large enough of characterize angiographically. All patients will first undergo a CT arteriogram of the target tumor. Patients will then receive 2 treatments on 2 consecutive weeks. The primary endpoint will be toxicity, with secondary endpoint of response as measured on week 4. This pilot study will also determine how technically feasible it is to locate the blood supply to these tumors and deliver cisplatin. If the first 6 patients do well, 6 additional patients will be accrued for a total of 12.

NCT ID: NCT01113476 Completed - Advanced Cancer Clinical Trials

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Start date: April 27, 2010
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

NCT ID: NCT01112280 Completed - Colorectal Neoplasm Clinical Trials

Efficacy of Cap-assisted Chromoendoscopy as a Screening Test for Colorectal Neoplasm Using Web-based Research Network

CapACE
Start date: April 2010
Phase: N/A
Study type: Interventional

The investigators plan to conduct a multi-center, randomized controlled trial to investigate the efficacy of cap-assisted chromoendoscopy as a screening test for detection of colorectal polyp. This study will be performed using web-based research network, e-VELOS in Korea.

NCT ID: NCT01104714 Completed - Clinical trials for Carcinoma, Squamous Cell

Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers

APPROCHE ORL
Start date: April 2010
Phase: N/A
Study type: Observational

The purpose of this study is to determine if there is a correlation between tumor response after 3 doses of chemotherapy by induction using Docetaxel, Cisplatine and 5-Fluorouracile for advanced stage epidermoid carcinomas of the upper aero digestive tract and the presence of one or a combination of 3 genetic polymorphisms and/or 5 intra-tumoral transcriptional modifications.

NCT ID: NCT01104077 Completed - Pancreatic Cancer Clinical Trials

Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)

Start date: November 17, 2008
Phase:
Study type: Observational

This is a retrospective observational study to determine the proportion of patients with a family history of pancreatic cancer and other malignancies among patients who have intraductal papillary mucinous neoplasm (IPMN). The investigators will be reviewing the demographic, clinical, radiologic, pathologic, and follow-up information from the Pancres Center database. The investigators will also conduct a chart review to collect information recorded by clinicians on each subject's family history of malignancy and personal history of malignancy. Results of this database and chart review will be incorporated into a datasheet in which all patient identifiers have been removed. The primary outcome will be the percentage of IPMN patients with at least one first-degree relative with pancreatic cancer or IPMN, or at least two first or second degree relatives with pancreatic cancer, IPMN, or malignancies related to pancreatic cancer syndromes, including colorectal, gastric, breast, ovarian, and melanoma neoplasms. Secondary outcomes will be the relative risk of IPMN subtypes of higher malignant potential (main duct or mixed type location), more advanced histology (carcinoma in situ or invasive carcinoma), and recurrence following surgical resection amongst subjects with a family history.

NCT ID: NCT01103791 Completed - Clinical trials for Advanced Solid Malignancies

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies.

NCT ID: NCT01103310 Completed - Neoplasms Clinical Trials

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Start date: April 2010
Phase: Phase 1
Study type: Interventional

Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY94-9392 in patients with cancer or inflammation.

NCT ID: NCT01102400 Completed - Clinical trials for Advanced Solid Malignancies

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).